DaVita's second quarter marked a decisive inflection in the company's post-cyber-incident normalization, with operating cash flow surging 61 percent year-to-date to $811 million as billing systems stabilized and working capital pressures abated. The quarter revealed a business returning to its structural rhythm: treatment volumes growing on patient count expansion, revenue per treatment rising 3.6 percent year-to-date on Medicare rate increases, and operating leverage expanding modestly despite persistent payor-mix headwinds. What separates this quarter from prior cycles is the convergence of three forces: volume growth at 2.4 percent year-to-date, rate tailwinds from the 2026 Medicare ESRD update, and a capital allocation machine that deployed $1.37 billion in share repurchases over the trailing twelve months, each reinforcing the other in a way the market has not fully priced.
The investment thesis rests on three variables. First, treatment volume trajectory: the company guided that patient count growth, not day-count seasonality, drives the durable volume component, and the six-month run rate suggests 1.5 to 2 percent annualized growth that compounds on a 2.5 million treatment base. Second, revenue per treatment durability: the 3.6 percent year-to-date increase reflects Medicare base-rate adjustments and commercial rate negotiations that have historically proven stickier than consensus models assume, with the proposed 1.1 percent 2027 ESRD PPS update providing a visible floor. Third, capital allocation optionality: with $1.37 billion remaining under authorization and a leverage profile that management has signaled can sustain mid-teens repurchase yields, the equity shrinkage rate creates a per-share earnings accelerator that operates independently of operating performance.
What confirms the thesis is sustained operating cash flow above $1.5 billion annually combined with treatment volume growth exceeding 1.5 percent, which would validate the volume-rate compounding dynamic. What breaks it is a reversal in commercial payor mix toward government rates that compresses revenue per treatment below $410, or a CMS final rule that delivers less than 0.5 percent ESRD PPS growth, which would signal structural rate stagnation. The re-rating trigger is not a single quarter but the market recognizing that DaVita's free cash flow yield, currently near 12 percent on enterprise value, is sustainable and growing, not a cyclical peak.